Biogen beats estimates to make solid start to key year
US biotech company Biogen (Nasdaq: BIIB) beat analysts’ expectations with its first-quarter 2023 financial results, exceeding forecasts with both sales and earnings figures.
The Boston-based firm recorded quarterly revenue of $2.46 billion, down 3% on a year ago but ahead of the Wall Street consensus estimate of $2.34 billion. Earnings per share dropped by 6% to $3.40, but again above the analyst estimate of $3.28.
"We continued to make strong progress against our business priorities, most importantly execution of three potential launches in 2023"Biogen reaffirmed its 2023 guidance, which is for a mid-single digit percentage decline in revenue versus 2022, and earnings per share of between $15 and $16.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze